<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nimodipine: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nimodipine: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nimodipine: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="10909" href="/d/html/10909.html" rel="external">see "Nimodipine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709172"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Inadvertent intravenous administration:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Do not administer nimodipine intravenously (IV) or by other parenteral routes. Deaths and serious, life-threatening adverse reactions have occurred when the contents of nimodipine capsules have been injected parenterally.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20865261"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nymalize</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867689"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Nimotop</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F201659"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Calcium Channel Blocker;</li>
<li>
                        Calcium Channel Blocker, Dihydropyridine</li></ul></div>
<div class="block doa drugH1Div" id="F201618"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> For enteral administration <b>ONLY.</b> Nimodipine oral solution (3 mg/mL) has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6bb43b5d-eafa-4e3a-b573-f25cb6d2da10">Subarachnoid hemorrhage</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Subarachnoid hemorrhage:</b>
<b>Oral:</b> 60 mg every 4 hours for 21 consecutive days. <b>Note:</b> Start therapy within 96 hours of the onset of subarachnoid hemorrhage.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991019"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer's labeling. However, nimodipine undergoes minimal renal elimination and dose adjustment may not be necessary. Not removed by hemo- or peritoneal dialysis; supplemental dose is not necessary.</p></div>
<div class="block doha drugH1Div" id="F50988234"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Cirrhosis: 30 mg every 4 hours for 21 consecutive days.</p></div>
<div class="block dot drugH1Div" id="F58432932"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Hypotension:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Optimal management is not clearly defined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37202712']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37202712'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">May consider halving dose and administering more frequently (eg, 30 mg every 2 hours); discontinuation of therapy may be necessary if hypotension persists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36880540','lexi-content-ref-37202712','lexi-content-ref-20398858']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36880540','lexi-content-ref-37202712','lexi-content-ref-20398858'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F201619"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing; use with caution.</p></div>
<div class="block adr drugH1Div" id="F201586"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Decreased blood pressure (4% to 5%), bradycardia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anemia, decreased platelet count, diaphoresis, disseminated intravascular coagulation, dizziness, edema, flushing, gastrointestinal hemorrhage, gastrointestinal pseudo-obstruction, hematoma, hepatitis, hypertension, increased lactate dehydrogenase, increased serum alkaline phosphatase, increased serum ALT, increased serum glucose, intestinal obstruction, jaundice, muscle cramps, palpitations, pruritus, psoriasis (Song 2021), rebound vasospasm, thrombocytopenia, vomiting, wheezing</p></div>
<div class="block coi drugH1Div" id="F201599"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Concomitant use with strong CYP3A4 inhibitors (eg, clarithromycin, telithromycin, delavirdine, indinavir, nelfinavir, ritonavir, saquinavir, ketoconazole, itraconazole, voriconazole, and nefazodone).</p>
<p style="text-indent:-2em;margin-left:4em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:4em;">Nymalize: There are no contraindications listed in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to nimodipine or any component of the formulation; concomitant use with phenobarbital, phenytoin, carbamazepine, or rifampin</p></div>
<div class="block war drugH1Div" id="F201583"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angina/MI: Increased angina and/or MI have occurred with initiation or dosage titration of dihydropyridine calcium channel blockers. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta-blockade.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Symptomatic hypotension with or without syncope can occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Monitor blood pressure closely during treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with cirrhosis due to the increased plasma concentrations of nimodipine and an increased risk of adverse reactions; a lower dose and close monitoring of blood pressure and heart rate are required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy with outflow tract obstruction: Use with caution in patients with hypertrophic cardiomyopathy with outflow tract obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Inadvertent IV administration: When inadvertently administered IV, fatality may occur; precautions (eg, adequate labeling, use of oral syringes) should be employed against such an event.</p></div>
<div class="block prod-avail drugH1Div" id="F55949507"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;">Nimodipine oral solution (3 mg/mL) has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F201592"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nymalize: 30 mg/10 mL (10 mL [DSC]); 60 mg/20 mL (20 mL [DSC], 473 mL [DSC]); 6 mg/mL (5 mL, 10 mL, 237 mL) [contains alcohol, usp, methylparaben, polyethylene glycol (macrogol)]</p></div>
<div class="block geq drugH1Div" id="F201579"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F201601"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (niMODipine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $19.23</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Nymalize Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6 mg/mL (per mL): $11.76</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867690"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nimotop: 30 mg</p></div>
<div class="block adm drugH1Div" id="F201596"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>For enteral administration ONLY. Life-threatening adverse events have occurred when administered parenterally.</b></p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i> Administer at least 1 hour before or 2 hours after meals.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> Administer without regards to meals; but administer consistently either with or without meals. Tablet should be swallowed whole with an adequate amount of fluid (eg, glass of water). Do not crush tablet. Avoid alkaline mixtures for 2 hours before or after administration. Patient should not be lying down during administration.</p>
<p style="text-indent:-2em;margin-left:2em;">NG or gastric tube administration:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution (Nymalize): <b>Note:</b> Administer at least 1 hour before or 2 hours after meals. Oral solution is available as a 3 mg/mL concentration supplied in a bulk bottle or unit-dose cup <b>or</b> as a 6 mg/mL concentration supplied in a bulk bottle or prefilled oral syringe.</p>
<p style="text-indent:-2em;margin-left:6em;">3 mg/mL concentration (bulk bottle or unit-dose cup): Administer using the supplied oral syringe labeled "<b>ORAL USE ONLY</b>." Following administration, refill the oral syringe with 20 mL of NS and flush any remaining contents from NG or gastric tube into the stomach.</p>
<p style="text-indent:-2em;margin-left:6em;">6 mg/mL concentration (bulk bottle or prefilled oral syringe): Following administration, refill oral syringe with 10 mL of NS and flush any remaining contents from NG or gastric tube into the stomach.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Administer at least 1 hour before or 2 hours after meals. If the capsules cannot be swallowed, the liquid may be removed by making a hole in each end of the capsule with an 18-gauge needle and extracting the contents into a syringe; transfer these contents into an oral syringe (amber-colored oral syringe preferred for storage). It is strongly recommended that preparation be done in the pharmacy. Label oral syringe with <b>"WARNING: For ORAL use only”</b> or <b>“Not for IV use”</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15332701']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15332701'])">Ref</a></span>). Follow administration with a flush of 30 mL NS.</p></div>
<div class="block use drugH1Div" id="F201595"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Subarachnoid hemorrhage:</b> For the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage from ruptured intracranial aneurysms regardless of post-ictus neurological condition (ie, Hunt and Hess grades I to V) (AHA/ASA [Hoh 2023]; NCS [Treggiari 2023]; manufacturer’s labeling).</p></div>
<div class="block mst drugH1Div" id="F201666"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">NiMODipine may be confused with niCARdipine, NIFEdipine, nisoldipine</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">
<b> Inadvertent intravenous administration; </b> For patients unable to swallow a capsule, the drug should be dispensed in an oral syringe (preferably amber in color) labeled <b>"WARNING: For ORAL use only"</b> or <b>"Not for IV use."</b> Nimodipine has inadvertently been administered IV when withdrawn from capsules into a syringe for subsequent nasogastric tube administration. Severe cardiovascular adverse events, including fatalities, have resulted. Employ precautions against such an event.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F201653"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F201588"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cladribine: Inhibitors of Equilibrative Nucleoside (ENT1) and Concentrative Nucleoside (CNT3) Transport Proteins may increase the serum concentration of Cladribine.  Management: Avoid concomitant use of ENT1 or CNT3 inhibitors during the 4 to 5 day oral cladribine treatment cycles whenever possible. If combined, consider an ENT1 or CNT3 inhibitor dose reduction and separation in the timing of administration.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of NiMODipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of NiMODipine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Weak): May decrease the serum concentration of NiMODipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of NiMODipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of NiMODipine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Weak): May increase the serum concentration of NiMODipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: May increase the serum concentration of NiMODipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of NiMODipine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of NiMODipine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F201610"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Administration of capsules with a standard breakfast results in a 68% lower maximum plasma concentration and 38% lower bioavailability as compared to administration under fasted conditions. In addition, AUC and maximum plasma concentration were increased by an average of 51% and 24%, respectively, following administration of nimodipine with grapefruit juice (Fuhr 1998). Management: Administer capsules on an empty stomach, at least 1 hour before or 2 hours after meals. Avoid concurrent use of grapefruit juice and nimodipine capsules or tablets [Canadian product].</p></div>
<div class="block pri drugH1Div" id="F201602"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nimodipine crosses the placenta (Belfort 1994).</p>
<p style="text-indent:0em;margin-top:2em;">Fetal outcome data following maternal use of nimodipine during pregnancy are limited (Magee 1996; Weber-Schoendorfer 2008).</p>
<p style="text-indent:0em;margin-top:2em;">The management of subarachnoid hemorrhage in pregnant patients is generally managed the same as nonpregnant patients, considering the trimester at presentation. However, data describing use of nimodipine are limited and use should consider the fetal risks of maternal hypotension (Ascanio 2019; Beighley 2021; Fritzsche 2017; Robba 2016; Toossi 2019; Wilson 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Nimodipine is known to cause cerebral vasodilation and hypotension, and therefore has been evaluated for the treatment of hypertension and prevention of seizures in patients with preeclampsia (Belfort 1994; Belfort 2003). However, nimodipine is not as effective as other agents in reducing high BP or reducing the risk of developing eclampsia and is not currently recommended for the management of preeclampsia (ACOG 2020; Duley 2013).</p></div>
<div class="block brc drugH1Div" id="F21123243"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Nimodipine is present in breast milk (Carcas 1996; Tonks 1995).</p>
<p style="text-indent:-2em;margin-left:2em;">Data related to the presence of nimodipine in breast milk are available from 2 case reports. Oral nimodipine 60 mg every 4 hours for 10 days was administered to a woman ~3 days postpartum for the treatment of a subarachnoid hemorrhage. Breast milk and maternal serum were sampled every 3 hours for 24 hours, following 7 days of therapy. Although variable, nimodipine breast milk levels were approximately one-third of the maternal plasma concentrations. The highest breast milk concentration was ~3.5 ng/mL (Tonks 1995). Nimodipine was administered IV to a woman ~3 weeks postpartum as an infusion of 1 mg/hour over 2 hours, then 2 mg/hour up to 24 hours (total dose: 46 mg). The highest milk concentration (4.7 ng/mL) occurred ~2 hours after the infusion was completed. Authors of the study calculated the relative infant dose (RID) of nimodipine to be between 0.008% and 0.092% of the weight adjusted maternal dose, providing an estimated daily infant dose via breast milk of 0.063 and 0.705 mcg/kg/day (Carcas 1996). In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F54372353"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BP and heart rate.</p></div>
<div class="block pha drugH1Div" id="F201582"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Nimodipine shares the pharmacology of other calcium channel blockers; animal studies indicate that nimodipine has a greater effect on cerebral arterials than other arterials; this increased specificity may be due to the drug's increased lipophilicity and cerebral distribution as compared to nifedipine; inhibits calcium ion from entering the “slow channels” or select voltage sensitive areas of vascular smooth muscle and myocardium during depolarization</p></div>
<div class="block phk drugH1Div" id="F201598"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensively hepatic via CYP3A4; undergoes first-pass metabolism.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Capsule/oral solution: 13%; Tablet [Canadian product]: 16% (range: 3% to 30%).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 1 to 2 hours; prolonged with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 0.25 to 1.05 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&lt;1% as unchanged drug); feces.</p></div>
<div class="block phksp drugH1Div" id="F51154899"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with cirrhosis, bioavailability is increased and C<sub>max</sub> almost doubles.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC and C<sub>max</sub> were ~2-fold higher in elderly patients compared with younger patients; this response is not considered clinically significant.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F201603"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Nivas</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nimodipine juno | Nimotop</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dilceren | Nimotop S</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Nimotop | Noodipina | Oxigen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Nimodipino | Nimotop | Regental</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ai bang | Bei qing | Ji li | Mai dao tong | Mai te ling | Ni kang pu da | Ni li su | Nimotop | Ou Neng | Yi fu lin | You ni xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Nimodipino | Nimotop | Nisom</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Dilceren | Nimotop S</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Nimodipin carino | Nimotop S</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Nimotop | Regental</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Nimotop | Vasoactin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Dilceren | Nimotop</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Brainal | Nimotop</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Admon | Brainal | Nimodipino G.e.s. | Nimotop | Remontal</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Nimotop | Nimovac-V</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Nimotop S</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Ceremax | Nimotop</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Modipin | Nimodec | Nimodip | Vasotop</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nimotop | Periplum</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nimotop | Reyon nimodipine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Dilceren | Nimodipin carino | Nimotax | Nimotop S</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dilceren | Nimotop S</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Modine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Bre nidip | Derinex | Eugerial | Nimodipino | Nimodipino gi kend | Nimotop</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Irrigor | Nimotop</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bredin | Nimotop</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Nimotop S</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Modina | Nimodipina | Nimodipina Aps | Nimotop</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Irrigor | Modip | Modipin</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Dilceren</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Dilceren | Nimodipine native | Nimopine | Nimotop</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Nimotop S</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Dilceren | Nimotop S</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Dilceren | Nimotop</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Inimod | Nimoion | Nimotop</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Nimodipina | Nimotop | Tropocer</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Nimotop</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-32443079">
<a name="32443079"></a>American College of Obstetricians and Gynecologists (ACOG). Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. <i>Obstet Gynecol</i>. 2020;135(6):e237-e260. doi:10.1097/AOG.0000000000003891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/32443079/pubmed" id="32443079" target="_blank">32443079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29476390">
<a name="29476390"></a>Ascanio LC, Maragkos GA, Young BC, Boone MD, Kasper EM. Spontaneous intracranial hemorrhage in pregnancy: a systematic review of the literature. <i>Neurocrit Care</i>. 2019;30(1):5-15. doi:10.1007/s12028-018-0501-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/29476390/pubmed" id="29476390" target="_blank">29476390</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33409763">
<a name="33409763"></a>Beighley A, Glynn R, Scullen T, et al. Aneurysmal subarachnoid hemorrhage during pregnancy: a comprehensive and systematic review of the literature. <i>Neurosurg Rev</i>. 2021;44(5):2511-2522. doi:10.1007/s10143-020-01457-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/33409763/pubmed" id="33409763" target="_blank">33409763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12540643">
<a name="12540643"></a>Belfort MA, Anthony J, Saade GR, Allen JC Jr; Nimodipine Study Group. A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia. <i>N Engl J Med</i>. 2003;348(4):304-311. doi:10.1056/NEJMoa021180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/12540643/pubmed" id="12540643" target="_blank">12540643</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8059821">
<a name="8059821"></a>Belfort MA, Saade GR, Moise KJ Jr, et al. Nimodipine in the management of preeclampsia: maternal and fetal effects. <i>Am J Obstet Gynecol</i>. 1994;171(2):417-424. doi:10.1016/0002-9378(94)90277-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/8059821/pubmed" id="8059821" target="_blank">8059821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8835048">
<a name="8835048"></a>Carcas AJ, Abad-Santos F, de Rosendo JM, et al. Nimodipine transfer into human breast milk and cerebrospinal fluid. <i>Ann Pharmacother</i>. 1996;30(2):148-150. doi:10.1177/106002809603000208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/8835048/pubmed" id="8835048" target="_blank">8835048</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23900968">
<a name="23900968"></a>Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. <i>Cochrane Database Syst Rev</i>. 2013;2013(7):CD001449. doi:10.1002/14651858.CD001449.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/23900968/pubmed" id="23900968" target="_blank">23900968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29041013">
<a name="29041013"></a>Fritzsche FS, Regelsberger J, Schmidt NO, et al. Maternal aneurysmal subarachnoid hemorrhage during pregnancy as an interdisciplinary task. <i>Z Geburtshilfe Neonatol</i>. 2017;221(6):276-282. doi:10.1055/s-0043-119363<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/29041013/pubmed" id="29041013" target="_blank">29041013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9562227">
<a name="9562227"></a>Fuhr U, Maier-Brüggemann A, Blume H, et al, “Grapefruit Juice Increases Oral Nimodipine Bioavailability,” <i>Int J Clin Pharmacol Ther</i>, 1998, 36(3):126-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/9562227/pubmed" id="9562227" target="_blank">9562227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15332701">
<a name="15332701"></a>Green AE, Banks S, Jay M, Hatton J. Stability of nimodipine solution in oral syringes. <i>Am J Health Syst Pharm</i>. 2004;61(14):1493-1496. doi:10.1093/ajhp/61.14.1493<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/15332701/pubmed" id="15332701" target="_blank">15332701</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37212182">
<a name="37212182"></a>Hoh BL, Ko NU, Amin-Hanjani S, et al. 2023 guideline for the management of patients with aneurysmal subarachnoid hemorrhage: a guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2023;54(7):e314-e370. doi:10.1161/STR.0000000000000436<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/37212182/pubmed" id="37212182" target="_blank">37212182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8633650">
<a name="8633650"></a>Magee LA, Schick B, Donnenfeld AE, et al. The safety of calcium channel blockers in human pregnancy: a prospective, multicenter cohort study. <i>Am J Obstet Gynecol</i>. 1996;174(3):823-828. doi:10.1016/s0002-9378(96)70307-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/8633650/pubmed" id="8633650" target="_blank">8633650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36880540">
<a name="36880540"></a>Mahmoud SH, Hefny FR, Panos NG, et al. Comparison of nimodipine formulations and administration techniques via enteral feeding tubes in patients with aneurysmal subarachnoid hemorrhage: a multicenter retrospective cohort study. <i>Pharmacotherapy</i>. 2023;43(4):279-290. doi:10.1002/phar.2791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/36880540/pubmed" id="36880540" target="_blank">36880540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Avet.1">
<a name="Avet.1"></a>Nimodipine [prescribing information]. East Brunswick, NJ: Avet Pharmaceuticals Inc; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nimotop.1">
<a name="Nimotop.1"></a>Nimotop (nimodipine) [product monograph]. Toronto, Ontario, Canada: Bayer Inc; November 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nymalize.1">
<a name="Nymalize.1"></a>Nymalize (nimodipine) [prescribing information]. Woburn, MA: Azurity Pharmaceuticals Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nymalize.2">
<a name="Nymalize.2"></a>Nymalize (nimodipine) 6 mg solution [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals LLC; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20398858">
<a name="20398858"></a>Rabinstein AA, Lanzino G, Wijdicks EF. Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage. <i>Lancet Neurol.</i> 2010;9(5):504-19. doi:10.1016/S1474-4422(10)70087-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/20398858/pubmed" id="20398858" target="_blank">20398858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26724616">
<a name="26724616"></a>Robba C, Bacigaluppi S, Bragazzi NL, et al. Aneurysmal subarachnoid hemorrhage in pregnancy-case series, review, and pooled data analysis. <i>World Neurosurg</i>. 2016;88:383-398. doi:10.1016/j.wneu.2015.12.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/26724616/pubmed" id="26724616" target="_blank">26724616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7575306">
<a name="7575306"></a>Tonks AM. Nimodipine levels in breast milk. <i>Aust N Z J Surg</i>. 1995;65(9):693-694. doi:10.1111/j.1445-2197.1995.tb00684.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/7575306/pubmed" id="7575306" target="_blank">7575306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29998426">
<a name="29998426"></a>Toossi S, Moheet AM. Intracerebral hemorrhage in women: a review with special attention to pregnancy and the post-partum period. <i>Neurocrit Care</i>. 2019;31(2):390-398. doi:10.1007/s12028-018-0571-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/29998426/pubmed" id="29998426" target="_blank">29998426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37202712">
<a name="37202712"></a>Treggiari MM, Rabinstein AA, Busl KM, et al. Guidelines for the neurocritical care management of aneurysmal subarachnoid hemorrhage. <i>Neurocrit Care.</i> Published online May 18, 2023. doi:10.1007/s12028-023-01713-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/37202712/pubmed" id="37202712" target="_blank">37202712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18585452">
<a name="18585452"></a>Weber-Schoendorfer C, Hannemann D, Meister R, et al. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study. <i>Reprod Toxicol</i>. 2008;26(1):24-30. doi:10.1016/j.reprotox.2008.05.065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/18585452/pubmed" id="18585452" target="_blank">18585452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15819768">
<a name="15819768"></a>Wilson SR, Hirsch NP, Appleby I. Management of subarachnoid haemorrhage in a non-neurosurgical centre. <i>Anaesthesia</i>. 2005;60(5):470-485. doi:10.1111/j.1365-2044.2005.04152.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nimodipine-drug-information/abstract-text/15819768/pubmed" id="15819768" target="_blank">15819768</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9702 Version 355.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
